Olmesartán/Amlodipino/Hidroclorotiazida Teva (Olmesartan Medoxomil, Hydrochlorothiazide, Amlodipine Besilate)

Olmesartan medoxil/amlodipine/hydrochlorothiazide is used in the management of hypertension, acting on several physiological pathways that regulate blood pressure.

• Essential hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk.
• Hypertension with edema: provides vasodilation and diuresis to alleviate fluid retention.
• Hypertension in patients with diabetes: helps protect renal function while controlling blood pressure.
• Resistant hypertension: adds an ARB, calcium‑channel blocker and thiazide diuretic for synergistic effect.
• Hypertension post‑myocardial infarction: contributes to secondary prevention by maintaining target blood pressure levels.

• The combination product blocks angiotensin II receptors (olmesartan), inhibits calcium influx into vascular smooth muscle (amlodipine), and reduces sodium reabsorption in the distal tubules (hydrochlorothiazide). Together these actions decrease peripheral vascular resistance, lower blood volume, and promote vasodilation, resulting in sustained blood‑pressure reduction.

Common Side Effects

• Headache: mild to moderate intensity, often transient.
• Peripheral edema: swelling of ankles or feet due to vasodilatory effect.
• Dizziness or light‑headedness: especially after the first doses.
• Fatigue: general feeling of tiredness.
• Cough: occasional dry cough.
• Increased urination: related to the diuretic component.

Serious or Rare Side Effects

• Angio‑edema: rapid swelling of lips, tongue or throat requiring emergency care.
• Severe hypotension: marked drop in blood pressure causing fainting.
• Electrolyte disturbances: significant changes in potassium or sodium levels.
• Acute kidney injury: sudden decline in renal function.
• Liver function abnormalities: elevated transaminases.
• Blood dyscrasias: rare blood cell count abnormalities.

Before initiating therapy, assess renal function, electrolytes and blood pressure response.

• Monitor blood pressure: ensure target levels are achieved without excessive drop.
• Check renal function: adjust dosing if creatinine clearance is reduced.
• Review electrolyte status: watch for potassium or sodium imbalances.
• Evaluate for heart failure: monitor for signs of fluid overload or worsening edema.
• Avoid concurrent use with other potent vasodilators: may increase hypotension risk.
• Store at ambient temperature: keep below 25°C, retain in original packaging and protect from moisture.

Olmesartan/amlodipine/hydrochlorothiazide may interact with several drug classes.

Major Interactions (Avoid)

• Dual renin‑angiotensin system blockade: concurrent ACE inhibitors or aliskiren can increase risk of renal impairment and hyperkalaemia.
• Potassium‑sparing diuretics: may cause dangerous hyperkalaemia.
• Strong CYP3A4 inhibitors: can raise amlodipine levels, increasing hypotension risk.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function.
• Lithium: may increase lithium levels, risking toxicity.
• Antidiabetic agents: may enhance glucose‑lowering effect, requiring dose adjustment.
• Alcohol: additive hypotensive effect, especially after initial dosing.
• Digoxin: increased risk of digoxin toxicity due to electrolyte shifts.